Hikal Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
Concerns
- Currently loss-making (EPS ₹-4)
- Low capital efficiency (ROCE 3.5%)
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,899 | ₹4.6L Cr | 36.1 | 5.46 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,100 | ₹2.4L Cr | 81.1 | 14.42 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,857 | ₹1.8L Cr | 82.8 | 19.58 | 27.4 | 15.2 | 0.33 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,650 | ₹1.2L Cr | 59.1 | 13.13 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,385 | ₹1.1L Cr | 31.3 | 3.25 | 11.6 | 15.5 | 0.01 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,120 | ₹1.1L Cr | 23 | 4.16 | 21.2 | 21.1 | 0.38 |
| LAURUSLABS Laurus Labs Limited | ₹1,840 | ₹99K Cr | 90.9 | 18.74 | 18.3 | 17.8 | 0.46 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
HIKAL · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 68.85% | 68.85% | 68.85% | 68.85% | 68.85% | 68.85% |
| FII | 6.14% | 6.55% | 6.66% | 6.78% | 6.06% | 5.70% |
| DII | 3.15% | 3.53% | 3.17% | 3.58% | 3.48% | 3.80% |
| Public | 21.85% | 21.06% | 21.32% | 20.79% | 21.61% | 21.65% |
Latest News
All newsHikal announces board meeting outcome.
*Hikal announces board meeting outcome.* The company disclosed the results of its recent board meeting held on August 26, 2026. No major financial decisions or strategic announcements were revealed. The update is primarily procedural in nature. 📊 *STOCKS:* HIKAL | 🏢 *SECTOR:* Pharma | #LOWIMPACT #BoardMeeting
Hikal reports Q1FY26 financial results
*Hikal reports Q1FY26 financial results* — Hikal Limited has announced its financial results for the quarter ended June 30, 2026. The company reported **revenue of ₹** and **net profit of ₹**, reflecting **X%** growth year-on-year. Results were in line with market expectations. 📊 *STOCKS:* $HIKAL | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Earnings
Hikal hosts analyst and investor meet
*Hikal hosts analyst and investor meet* to discuss business updates. The event is part of routine investor engagement. No major financial announcements were disclosed. Details shared are primarily forward-looking and operational in nature. 📊 *STOCKS:* $HIKAL | 🏢 *SECTOR:* CapitalMarkets | #LOWIMPACT #InvestorMeet
Hikal Limited publishes mandatory newspaper notice
*Hikal Limited publishes mandatory newspaper notice* as part of regulatory compliance. This routine corporate filing does not disclose any financial or operational update. Such notices are standard for public disclosures under listing norms. No immediate market-moving information was shared. 📊 *STOCKS:* HIKAL | 🏢 *SECTOR:* CapitalMarkets | #LOWIMPACT #CorporateFiling
Hikal Limited announces general updates
*Hikal Limited announces general updates.* The company filed a routine corporate update with the NSE. No specific financial or operational details were disclosed. Such filings typically contain administrative or procedural information. 📊 *STOCKS:* $HIKAL | 🏢 *SECTOR:* CapitalMarkets | #LOWIMPACT #corporate
Hikal sets dividend record date for September 2026
*Hikal sets dividend record date for September 2026.* Hikal Limited has announced **04-Sep-2026** as the record date for dividend distribution. Shareholders registered on this date will be eligible for the payout. The quantum and payment date of the dividend will be disclosed later. 📊 *STOCKS:* $HIKAL | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Dividend
Hikal shares fall after newspaper publication notice
*Hikal shares fall after newspaper publication notice*. Hikal Limited filed a copy of its newspaper publication with the NSE, a routine disclosure. The notice contains no financial or operational updates. 📊 *STOCKS:* HIKAL | 🏢 *SECTOR:* CapitalMarkets | #LOWIMPACT #Hikal
About Hikal Limited
Hikal is a partner to companies in the Pharmaceuticals, Crop Protection, and Specialty Chemicals industry. The company is in the business of supplying research services, active ingredients and intermediates for its customers. Hikal's manufacturing facilities have been inspected and approved by leading multinational companies in the Crop protection and Pharmaceutical sectors. The Crop protection facilities are located at Taloja and Mahad {Maharashtra). The Pharmaceutical manufacturing facilities are situated in Jigani (Bengaluru) and Panoli (Gujarat). Hikal's R & D facilities are located in Pune.[1]
HealthcarePharmaceuticals & Biotechnology